ArticleJCO precision oncology2025
Precision Treatment of Patients With GI Cancer Using Pre-emptive
Article in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- DPYD and UGT1A1 Genotype-Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant-Specific Impact on Treatment Intensity and Toxicity.International journal of cancer · 2026Article
- The Impact of Upfront DihydroPyrimidine Dehydrogenase (DPD) Testing on the Therapeutic Management of Patients Scheduled for 5-FU.Cancer medicine · 2026Observational
- Advancing Precision Dosing of 5-FU: Population PK Model Development, Limited Sampling Strategies, and Fit-for-Use Application.Clinical pharmacokinetics · 2026Article
- Pharmacokinetics of 5-Fluorouracil in Patients Treated With Capecitabine Carrying the c.1236G>AJCO precision oncology · 2026Article
- Global Investigation of Clinical Implementation Strategies for DPYD Testing to Guide Fluoropyrimidine Therapy.Clinical and translational science · 2026Article
- Dihydropyrimidine Dehydrogenase-Guided Dosing of 5-Fluorouracil: Prioritizing Precision Over Dose Reduction.JCO precision oncology · 2025Article
- Reply to: Dihydropyrimidine Dehydrogenase Enzyme-Guided Dosing of 5-Fluorouracil: Prioritizing Precision Over Dose Reduction.JCO precision oncology · 2025Article
- A Lack of Complete Linkage Disequilibrium Between c.1236G>A and c.1129-5923C>G HapB3 Variants ofInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe Clinical Pharmacogenetics Implementation Consortium (CPIC) recommends screening for four common PATIENTS AND
methodsPatients were grouped into four variant categories (
resultsTwenty-six wild-type controls and 34
conclusionThe current CPIC guidelines are overly conservative for c.1236G>A/HapB3 and most p.D949V variants. A 75% starting dose is more appropriate for most c.1236G>A/HapB3 carriers. We recommend 5-FU therapeutic drug monitoring in all patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.